Efficacy and Safety of Setmelanotide, a Melanocortin-4 Receptor Agonist, for Obese Patients: A Systematic Review and Meta-Analysis.
MC4R agonist
RM-493
obesity
setmelanotide
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
04 Oct 2023
04 Oct 2023
Historique:
received:
02
09
2023
revised:
15
09
2023
accepted:
16
09
2023
medline:
27
10
2023
pubmed:
27
10
2023
entrez:
27
10
2023
Statut:
epublish
Résumé
A malfunction in the melanocortin-4 receptor (MC4R) is associated with obesity in rare genetic syndromes; setmelanotide is a new drug that activates this receptor and is being used to treat severe obesity. This meta-analysis evaluated the efficacy and safety of setmelanotide for weight loss in severe obesity linked to human MC4R deficiency. We searched PubMed, Embase, and Cochrane for randomized and nonrandomized clinical trials using setmelanotide. We considered a We included 376 patients, of whom 328 (87.2%) received setmelanotide for a mean follow-up of 52 weeks. The mean age was 32.8 (14.67) years. Weight loss was significant (MD -3.52; 95% CI -3.98, -3.05; Our results support the use of setmelanotide in treating severe obesity.
Sections du résumé
BACKGROUND
BACKGROUND
A malfunction in the melanocortin-4 receptor (MC4R) is associated with obesity in rare genetic syndromes; setmelanotide is a new drug that activates this receptor and is being used to treat severe obesity. This meta-analysis evaluated the efficacy and safety of setmelanotide for weight loss in severe obesity linked to human MC4R deficiency.
METHODS
METHODS
We searched PubMed, Embase, and Cochrane for randomized and nonrandomized clinical trials using setmelanotide. We considered a
RESULTS
RESULTS
We included 376 patients, of whom 328 (87.2%) received setmelanotide for a mean follow-up of 52 weeks. The mean age was 32.8 (14.67) years. Weight loss was significant (MD -3.52; 95% CI -3.98, -3.05;
CONCLUSIONS
CONCLUSIONS
Our results support the use of setmelanotide in treating severe obesity.
Identifiants
pubmed: 37888071
pii: jpm13101460
doi: 10.3390/jpm13101460
pmc: PMC10608339
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Lancet Diabetes Endocrinol. 2020 Dec;8(12):960-970
pubmed: 33137293
Skin Pharmacol Physiol. 2021;34(6):307-316
pubmed: 34058738
N Engl J Med. 2003 Mar 20;348(12):1085-95
pubmed: 12646665
Drug Des Devel Ther. 2015 Mar 30;9:1867-75
pubmed: 25848222
Expert Opin Pharmacother. 2020 Feb;21(3):275-285
pubmed: 31790314
Diabetes. 2008 Sep;57(9):2511-8
pubmed: 18559663
N Engl J Med. 2021 Mar 18;384(11):989-1002
pubmed: 33567185
Handb Exp Pharmacol. 2022;274:387-414
pubmed: 34783910
Endocr Rev. 2022 May 12;43(3):507-557
pubmed: 35552683
Nat Med. 2018 May;24(5):551-555
pubmed: 29736023
Mol Metab. 2017 Oct;6(10):1321-1329
pubmed: 29031731
Pharmacol Res. 2021 Jul;169:105649
pubmed: 33962014
Lancet. 2018 Aug 25;392(10148):637-649
pubmed: 30122305
Front Endocrinol (Lausanne). 2012 Feb 28;3:29
pubmed: 22645519
N Engl J Med. 2016 Jul 21;375(3):240-6
pubmed: 27468060
J Pharm Technol. 2022 Dec;38(6):368-373
pubmed: 36311304
Orphanet J Rare Dis. 2023 Jan 16;18(1):12
pubmed: 36647077
Cell Rep. 2022 Nov 1;41(5):111579
pubmed: 36323255
Indian J Med Res. 2020 Jan;151(1):11-21
pubmed: 32134010
Nutrition. 2020 Mar;71:110615
pubmed: 31864969
Rev Med Liege. 2021 Feb;76(2):134-139
pubmed: 33543861
JAMA. 2016 Jun 14;315(22):2424-34
pubmed: 27299618
Cell Metab. 2017 Mar 7;25(3):535-543
pubmed: 28273476
Diabetes Obes Metab. 2020 Nov;22(11):2133-2140
pubmed: 32627316
Lancet Diabetes Endocrinol. 2022 Dec;10(12):859-868
pubmed: 36356613
JAMA. 2022 Jan 11;327(2):138-150
pubmed: 35015037
Front Endocrinol (Lausanne). 2021 Jul 07;12:645563
pubmed: 34305810
JAMA. 2021 Jul 13;326(2):129-130
pubmed: 34160571